The civic record
Read. Follow. Verify.North Carolina requires prescription drug advertisements to disclose FDA approval dates and clinical trial…
Last action · February 11, 2025: Ref To Com On Rules, Calendar, and Operations of the House (House action)Sponsors: Harry Warren and 11 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
North Carolina requires prescription drug and manufacturers to include FDA approval dates, first-market dates, and specific details in consumer advertisements published in the state on or after October 1, 2025.
Consumers viewing prescription drug ads in North Carolina will receive expanded disclosure requirements regarding side effect frequencies, trial lengths, and participant counts.
- Prescription drug advertising is primarily regulated at the federal level by the Food and Drug Administration under the Federal Food, Drug, and Cosmetic Act. context
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Manufacturers of prescription drugs
Prescription drug manufacturers must update all consumer-facing advertisements in North Carolina to include FDA approval dates, market availability dates, and specific clinical trial metrics.
Consumers located in North Carolina
Consumers will see expanded risk disclosures, trial participant counts, trial lengths, and approval dates in prescription drug advertisements.
Key Facts
- Manufacturers must include the FDA approval date for the advertised use in any regulated prescription drug or biological product advertisement.
- Advertisements must disclose the date the product was first available for purchase by consumers in the United States.
- Advertisements listing side effects under federal law must include the length of the clinical trial evidencing the side effect.
- Advertisements must disclose the number of participants in the clinical trial.
Show all 9 facts
- Advertisements must state the frequency of the listed side effect by participant number or percentage.
- Biological products include viruses, therapeutic serums, toxins, antitoxins, vaccines, blood components, allergenic products, and proteins.
- A clinical trial is defined as an investigation involving human subjects to test efficacy intended for FDA submission.
- Regulated advertisements cover consumer-facing commercial messages via television, radio, internet, and print in North Carolina.
- The requirements apply to advertisements published in North Carolina on or after October 1, 2025.
Frequently Asked Questions
When do these advertising requirements take effect?
Which media types are covered by the advertising rules?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
3 actions- Feb 11, 2025HouseRef To Com On Rules, Calendar, and Operations of the House
- Feb 11, 2025HousePassed 1st Reading
- Feb 10, 2025HouseIntroducedFiled
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Show 7 more sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
State-Level Pharmaceutical Advertising Mandates
The bill establishes specific state-level clinical trial disclosure requirements for prescription drug advertisements that build upon federal standards.
Connected Entities
Sources
www.ncleg.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz35Current news / social attention level
Publisher tools
